This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): MEDI524, MEDI-524, motavizumab
Description: Numax is an enhanced potency humanized respiratory syncytial virus (RSV) monoclonal antibody.
Deal Structure: Numax was originally developed by MedImmune.
In 2005, MedImmune and Abbott International (AI) amended the international distribution agreement for Synagis to include rights for the exclusive, potential future distribution of Numax (motavizumab), a second generation anti-RSV. Under the terms of the amended agreement, AI will be working to secure regulatory approval of Numax outside of the U.S. and, assuming receipt of such approval, will distribute and market Numax outside of the United States. As a part of this agreement, Medimmune will have the option to co-promote Numax with AI in up to seven countries outside of the United States.
In June 2007, AstraZeneca closed its acquisition of MedImmune.
Partners: AbbVie Inc.
Pink Sheet MedImmune files Synagis follow-on
Additional information available to subscribers only: